Increasing Ease of Cancer Diagnosis
Ease of cancer diagnosis has increased substantially over the past decade and is expected to increase further in the coming years. Currently, it is possible to diagnose different cancers, such as breast cancer and prostate cancer, with a simple blood test. The most widely accepted blood tests for breast cancer include BRCA1 and BRCA2. Similarly, conventional imaging technologies have also experienced considerable innovation in the recent past, and breast tomosynthesis is the best example. Breast tomosynthesis is less-painful and way more efficient than conventional mammography. More than 95% of the currently available cancer diagnostics require very minimal intervention and are capable of providing results with very high sensitivity and specificity. Due to this need of minimal intervention, patient compliance has increased in the recent years, which, in turn, has resulted in an increased number of tests, ultimately driving the market growth.
Other factors, such as increasing healthcare expenditure and the emergence of new technologies, like biomarkers and point of care testing, is increasing the growth of the cancer diagnostics market.
Limited Use in Emerging Markets
The emerging markets have the smallest market share in the overall cancer diagnostics market across the world, because of many region-specific factors. Limitations in the healthcare sector, in most emerging markets, are the reason behind the lack of universal health coverage. Most people cannot afford medical checkups that involve high expenditure, such as cancer diagnostics; lack of universal health coverage is worsening the situation. Along with this, most healthcare facilities in the region are not equipped to perform such high-quality tests. Other than this, the majority of the population in these markets lives in rural areas, with little or no access to even the basic healthcare facilities. Lack of disease awareness is also a major problem in the emerging markets, due to which, most of the population is diagnosed with cancer at a very late stage. These limitations are not only bound to blood tests, but also apply to that diagnosis, which uses imaging equipment and sampling devices. All these limitations are hindering the market growth. The other factor, where expensive diagnostic procedures and market being controlled by few players, are hindering the market growth of cancer diagnostics.
Asia-Pacific to Show the Fastest Growth Rate
North America is dominating the cancer diagnostics market, due to the presence of many biotechnology companies, as well as many medical device manufactures in the region. Asia-Pacific is expected to record a substantial growth over the forecast period, due to the existence of a large patient pool, availability of skilled professionals at a reasonable cost, and a distinct regulatory framework supporting accelerated product approvals.
Key Developments in the Market
- October 2017: Abbott acquired Alere Inc.
Reasons to Purchase the Report
- Current and future market outlook for cancer diagnostics in the developed and emerging markets
- Analyze various perspectives on the market, with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth, during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support, along with the market estimate sheet (in excel).
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Ease of Cancer Diagnosis
6.1.2 Increasing Healthcare Expenditure
6.1.3 Emergence of New Technologies such as Biomarkers and Point of Care Testing
6.2 Market Restraints
6.2.1 Limited Use in the Emerging Markets
6.2.2 Expensive Diagnostic Procedures
6.2.3 Market Controlled by Few Players
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation -by Products
7.1.1 Next-generation Sequencing
7.1.3 In situ Hybridization
7.1.5 Flow Cytometry
7.2 Segmentation -by Application
7.2.1 Colorectal Cancer
7.2.2 Breast Cancer
7.2.3 Lung Cancer
7.2.4 Cervical Cancer
7.2.5 Kidney Cancer
7.2.6 Liver Cancer
7.2.7 Pancreatic Cancer
7.3 Segmentation - by Geography
7.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 New Zealand
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
7.3.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of the Middle East & Africa
7.3.5 South America
188.8.131.52 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.3 F. Hoffmann-La Roche Ltd
9.4 Siemens Healthcare GmbH
9.5 Thermo Fisher Scientific Inc.
9.6 GE Healthcare
9.7 Hologic Inc.
9.8 Illumina Inc
9.9 Philips Healthcare
9.10 Agilent Technologies Inc
10. Future of the Market